camonsertib,Niraparib,Olaparib,Talazoparib
repare therapeutics,roche,gsk,astrazeneca,merck,pfizer
['tresr', 'attacc', 'camonsertib', 'repare,(-prepare)', 'reparetherap', '$rptx']
#reparetherapeutics presents initial clinical data from the phase 1/2 tresr and #attacc trials evaluating #camonsertib in combination with three #parpinhibitors at the #aacr23 $rptx 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.